The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women
Open accessAbstract
OBJECTIVE: To determine the safety and effectiveness of BufferGel and 0.5% PRO2000 microbicide gels for the prevention of male-to-female HIV transmission. DESIGN: Phase II/IIb, randomized, placebo-controlled trial with three double-blinded gel arms and an open-label no gel arm. METHODS: Study participants from Malawi, South Africa, Zambia, Zimbabwe, and the USA were instructed to apply study gel up to 1 h before each sex act and safety, sexual behavior, pregnancy, gel adherence, acceptability, and HIV serostatus were assessed during follow-up. RESULTS: The 3101 enrolled women were followed for an average of 20.4 months with 93.6% retention and 81.1% self-reported gel adherence. Adverse event rates were similar in all study arms. HIV incidence rates in the 0.5% PRO2000 gel, BufferGel, placebo gel, and no gel arms were 2.70, 4.14, 3.91, and 4.02 per 100 women-years, respectively. HIV incidence in the 0.5% PRO2000 gel arm was lower than the placebo gel arm (hazard ratio = 0.7, P = 0.10) and the no gel arm (hazard ratio = 0.67, P = 0.06). HIV incidence rates were similar in the BufferGel and both placebo gel (hazard ratio = 1.10, P = 0.63) and no gel control arms (hazard ratio = 1.05, P = 0.78). HIV incidence was similar in the placebo gel and no gel arms (hazard ratio = 0.97, P = 0.89). CONCLUSION: The 0.5% PRO2000 gel demonstrated a modest 30% reduction in HIV acquisition in women. However, these results were not statistically significant and subsequent findings from the Microbicide Development Programme (MDP) 301 trial have confirmed that 0.5% PRO2000 gel has little or no protective effect. BufferGel did not alter the risk of HIV infection. Both products were well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Skoler-Karpoff, S., Ramjee, G., Ahmed, K., Altini, L., Plagianos, M. G., Friedland, B., Govender, S., De Kock, A., Cassim, N., Palanee, T., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61842-5 · Cited by 502
Self-citationMcCormack, S., Ramjee, G., Kamali, A., Rees, H., Crook, A. M., Gafos, M., Jentsch, U., Pool, R., Chisembele, M., Kapiga, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61086-0 · Cited by 335 · cited 2×
“5 and 2% concentrations of PRO2000 gel, which has, subsequent to the presentation of the HPTN 035 trial results, shown that both concentrations of PRO2000 have little or no protective effect on HIV [21].”
BackgroundResultSelf-citationSAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.
Feldblum, P. J., Adeiga, A., Bakare, R., Wevill, S., Lendvay, A., Obadaki, F., Olayemi, M. O., Wang, L., Nanda, K., & Rountree, W. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001474 · Cited by 280 · cited 2×
“The Savvy trial was halted early owing to futility.”
Method
Cited by
HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities
Kharsany, A. B. M., & Karim, Q. A. (2016) · The Open AIDS Journal · doi:10.2174/1874613601610010034 · Cited by 980
Hormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis
Morrison, C. S., Chen, P.-L., Kwok, C., Baeten, J. M., Brown, J., Crook, A. M., Van Damme, L., Delany-Moretlwe, S., Francis, S. C., Friedland, B. A., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001778 · Cited by 355
Women and HIV in Sub-Saharan Africa
Ramjee, G., & Daniels, B. (2013) · AIDS Research and Therapy · doi:10.1186/1742-6405-10-30 · Cited by 341
Self-citationBacterial Vaginosis and the Risk of Trichomonas vaginalis Acquisition Among HIV-1–Negative Women
Balkus, J. E., Richardson, B. A., Rabe, L. K., Taha, T. E., Mgodi, N., Kasaro, M. P., Ramjee, G., Hoffman, I. F., & Abdool Karim, S. S. (2014) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000000075 · Cited by 89
Self-citationLotfi, H., Sheervalilou, R., & Zarghami, N. (2017) · BioImpacts · doi:10.15171/bi.2018.16 · Cited by 30
Metadata
- Authors
- Abdool Karim, S. S., Richardson, B. A., Ramjee, G., Hoffman, I. F., Chirenje, Z. M., Taha, T., Kapina, M., Maslankowski, L., Coletti, A., Profy, A., Moench, T. R., Piwowar-Manning, E., Mâsse, B., Hillier, S. L., & Soto-Torres, L.
- Venue
- AIDS
- Published
- 2011-04-24
- Volume
- 25
- Issue
- 7
- Pages
- 957-966
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2025396127
- Cited by
- 233
- References
- 4
- FWCI
- 27.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. https://app.cochat.ai/papers/10.1097/qad.0b013e32834541d9
- The paper
- Abdool Karim, S. S., Richardson, B. A., Ramjee, G., Hoffman, I. F., Chirenje, Z. M., Taha, T., Kapina, M., Maslankowski, L., Coletti, A., Profy, A., Moench, T. R., Piwowar-Manning, E., Mâsse, B., Hillier, S. L., & Soto-Torres, L. (2011). Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. https://doi.org/10.1097/qad.0b013e32834541d9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.